Earnings call transcript: Sanofi tops Q3 2026 forecasts and lifts guidance
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- SNY Sanofi
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Sanofi belongs to, so it often moves with news about it.
- NVS Novartis AG-0.1% 14d
Novartis AG is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+12.6% 30d
AstraZeneca is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-10.5% 30d
Novo Nordisk A/S is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk-8.1% 7d
Gsk is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+3.3% 11d
Roivant Sciences is a peer of Sanofi in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| SNY | -5.83% | -4.80% | base | +2.61% | +2.15% | +6.92% | after close |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | after close |
| NVS | -4.37% | -2.94% | base | +0.39% | -0.98% | +2.61% | after close |
| AZN | -7.79% | -9.17% | base | -0.02% | -1.47% | +1.27% | after close |
| NVO | -2.16% | -4.29% | base | +1.15% | +0.54% | +5.44% | after close |
| GSK | +3.20% | -1.53% | base | -0.79% | -1.58% | +3.29% | after close |
| ROIV | -2.30% | +0.50% | base | -2.76% | -2.30% | +3.55% | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Earnings call transcript: Sanofi tops Q3 2026 forecasts and lifts guidance Investing.com
Source: Investing.com
This story
| Company | When | Move | Status |
|---|---|---|---|
| AZN | that day | -0.02% | final price |
| AZN | the next day | -1.47% | final price |
| AZN | two days later | +1.27% | final price |
| AZN | three days earlier | -9.17% | final price |
| AZN | five days earlier | -7.79% | final price |
| GSK | that day | -0.79% | final price |
| GSK | the next day | -1.58% | final price |
| GSK | two days later | +3.29% | final price |
| GSK | three days earlier | -1.53% | final price |
| GSK | five days earlier | +3.20% | final price |
| NVO | that day | +1.15% | final price |
| NVO | the next day | +0.54% | final price |
| NVO | two days later | +5.44% | final price |
| NVO | three days earlier | -4.29% | final price |
| NVO | five days earlier | -2.16% | final price |
| NVS | that day | +0.39% | final price |
| NVS | the next day | -0.98% | final price |
| NVS | two days later | +2.61% | final price |
| NVS | three days earlier | -2.94% | final price |
| NVS | five days earlier | -4.37% | final price |
| ROIV | that day | -2.76% | final price |
| ROIV | the next day | -2.30% | final price |
| ROIV | two days later | +3.55% | final price |
| ROIV | three days earlier | +0.50% | final price |
| ROIV | five days earlier | -2.30% | final price |
| SNY | that day | +2.61% | final price |
| SNY | the next day | +2.15% | final price |
| SNY | two days later | +6.92% | final price |
| SNY | three days earlier | -4.80% | final price |
| SNY | five days earlier | -5.83% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 66 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 52 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 62 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 67 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
25 out of 100
“Earnings call transcript: Sanofi tops Q3 2026 forecasts and lifts guidance” scores 25 out of 100. The score uses 2 sources.